Lidocaine Aguettant

Lidocaine, the active ingredient in Lidocaine Aguettant, is a local anesthetic presented as a sterile solution for endotracheopulmonary use. Manufactured under EU standards, it provides temporary loss of sensation in the airway and pulmonary structures during diagnostic or therapeutic procedures requiring localized anesthesia of the trachea, bronchi, or lung tissue.

GNH USA supplies Lidocaine Aguettant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company ensures quality assurance, regulatory compliance, and reliable cold‑chain logistics where required.

Lidocaine Aguettant is used to provide local anesthesia in the endotracheopulmonary tract.

- Bronchoscopy: facilitates patient comfort and reduces cough reflex during airway examination. - Tracheal intubation: provides topical anesthesia to the tracheal mucosa to ease tube placement. - Pulmonary surgery: offers localized numbness of lung tissue during minimally invasive procedures.

Adverse reactions to Lidocaine Aguettant are generally related to its local anesthetic properties and systemic absorption.

Common Side Effects: - Mild burning sensation at the application site - Transient numbness of the treated area - Light‑headed dizziness - Nausea

Serious or Rare Side Effects: - Cardiac arrhythmias, including ventricular tachycardia - Seizures due to central nervous system toxicity - Severe allergic reaction (anaphylaxis) - Methemoglobinemia, a rare blood disorder

When using Lidocaine Aguettant, clinicians should observe several precautions to minimize risks.

- Patient assessment: evaluate for known hypersensitivity to amide‑type local anesthetics. - Cardiac history: avoid in patients with significant conduction disorders or arrhythmias. - Dosage limit: adhere to recommended maximum dose to prevent systemic toxicity. - Concomitant CNS depressants: use caution when combined with other agents that lower seizure threshold. - Pregnancy and lactation: consider risk‑benefit ratio; use only if clearly needed. - Store at room temperature: keep in original container, protect from light and moisture.

Lidocaine Aguettant may interact with other medicines that affect cardiac conduction or central nervous system activity.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): additive cardiotoxicity. - Beta‑blockers: may enhance bradycardia. - CYP3A4 inhibitors (e.g., ketoconazole): increase lidocaine plasma levels.

Moderate Interactions (Monitor Closely): - Opioids: may increase sedation and respiratory depression. - Diuretics: may reduce plasma protein binding, raising free lidocaine. - Local anesthetic mixtures: risk of cumulative toxicity.